Questions? Feedback? powered by Olark live chat software
All Site

The xCELLigence Research Grant is aimed at helping scientists achieve their research goals by providing them free access to RTCA technology.

For 6 months, the research grant winner will be provided:
• xCELLigence Real Time Cell Analysis DP instrument
• Consumables (Up to $1000)
• Consultation for up to 6 months
ACEA is currently accepting xCELLigence Research Grant applications (Deadline June 14, 2019)

Applications, which are only a few pages in length, must be received by June 14th. The winner will be announced July 1.

apply for grant

Why Should You Analyze Cell Behavior in Real Time?

  • More sensitive than imaging or endpoint assays
  • Use low, physiologically relevant effector:target ratios
  • Continuously measure short-term killing kinetics for rapid screening or QC
  • Long-term monitoring demonstrates “serial killing” nature of immune cells
  • Label-free and non-invasive (no 51Cr, luciferase, etc.)

To learn more about the xCELLigence Real Time Cell Analysis assay, read the article "In vitro immunotherapy potency assays using real-time cell analysis" by Cerignoli et al. PLoS One. 2018.

Previous Grant Recipient

2018 Grant Recipient

Teresa KrabbeTERESA KRABBE, PhD student in the working group of Dr. Jennifer Altomonte, Klinikum Rechts der Isar of the Technical University Munich

Application: Oncolytic Viruses

Teresa Krabbe is awarded the xCELLigence Research Grant in December 2018 for her proposal to develop adoptive T cell therapy as a complimentary immunotherapeutic for an improved oncolytic virus platform.

“I am thrilled about the opportunity to work with the xCELLigence to continuously monitor tumor cells infected with our fusogenic oncolytic virus. It will greatly improve our ability to track the morphological changes that occur at very early stages of infection. We are additionally working on a combination of our oncolytic virus platform with TCR T cells and hope to illustrate a synergistic effect in vitro by real time cell analysis with the xCELLigence.”

2017 Grant Recipient

karen 150x150DR. KAREN WRIGHT, LECTURER IN BIOMEDICINE AT LANCASTER UNIVERSITY (UK)

Dr. Karen Wright received the xCELLigence Research Grant to study the role of the CB1 cannabinoid receptor in regulating intercellular tight junctions and permeability in intestinal epithelial cells during inflammation. Though the impact of oxygen concentration on metabolic activity and gene expression profiles has been well established, few cell-based assays attempt to model physiological O2. Working within an enclosed workstation that maintains physiological oxygen concentration, Wright will use the xCELLigence system to monitor both early CB1 receptor signaling events and their long term functional outcome.